Search Results for "Sunitinib"

22:05 EDT 29th July 2015 | BioPortfolio

Original Source: Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer. The safety of sunitinib malate will also be studied.

Matching Channels

None

Matching News

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Dr Mark Beresford talks to ecancertv at ASCO GU 2015 reflecting on the initial results of the ASSURE trial where adjuvant treatment with sorafenib or sunitinib is used for localised renal carcinoma...

Gemcitabine-Sunitinib Combo Active in Aggressive RCC

Patients with sarcomatoid or poor-risk renal cell carcinoma (RCC) had frequent objective responses when treated with the combination of gemcitabine (Gemzar) and sunitinib (Sutent), according to the re...

Chromosomal Changes Predict Clinical Response to Sunitinib in RCC

Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict CR to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).

Maintenance Sunitinib Improved PFS in Extensive-Stage SCLC

In a phase II study, the use of maintenance sunitinib improved progression-free survival among patients with untreated extensive-stage small-cell lung cancer.

Sorafenib nor Sunitinib Effective As Adjuvant Kidney Cancer Therapy

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the r...

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

Prof Figlin talks to ecancertv at ASCO GU 2015 about the use of sunitinib in renal cancer when combined with AGS-003, an autologous immunotherapy designed to induce an immune response to a patient...

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

Dr Naomi Balzer-Haas talks to ecancertv at ASCO GU 2015 about the initial results from the phase III ASSURE trial. It appears that adjuvant sorafenib or sunitinib do not benefit patients with unfavo...

Celldex begins Phase I/II trial of varlilumab-sunitinib combination to treat CC-RCC

US-based Celldex Therapeutics has started an open-label, Phase I/II safety and tolerability trial evaluating the investigational combination of varlilumab and sunitinib (Sutent) in patients with metas...

Matching PubMed Articles

AXL as a modulator of sunitinib response in glioblastoma cell lines.

Receptor tyrosine kinase (RTK) targeted therapy has been explored for glioblastoma treatment. However, it is unclear which RTK inhibitors are the most effective and there are no predictive biomarkers ...

Sunitinib - ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver and kidney in male and female mice differently.

Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. We assessed ...

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is ...

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.

The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed t...

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Previously published pharmacokinetics (PK) models for sunitinib and its active metabolite SU12662 were based on a limited dataset or lacked important elements such us correlations between sunitinib an...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement